KemiO
Moderator
The United States Food and Drug Administration has approved Tivicay (dolutegravir) to treat infection with HIV-1, an AIDS causing virus.
The drug’s safety and effectiveness were accessed in clinical research involving more than 2,500 adults and children.
Tivicay is produced by GlaxoSmithKline, based in Research Triangle Park, N.C, and may compete with other best selling drugs like Atripla on the market. It is used to ward off HIV in for both HIV patients who have never taken any medication to fight the virus and for those who have already tried other treatments.
The side effects included difficulty sleeping, headache, allergic-like reactions and abnormal liver function in people who had hepatitis B or C.
